CohBar, Inc. (CWBR)
OTCMKTS · Delayed Price · Currency is USD
0.4100
0.00 (0.00%)
Inactive · Last trade price on Jan 23, 2025
CohBar Company Description
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases.
It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases.
CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
Contact Details
Address: 1455 Adams Drive Menlo Park, Delaware 94025 United States | |
| Phone | 650 446 7888 |
| Website | cohbar.com |
Stock Details
| Ticker Symbol | CWBR |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US19249J1097 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pinchas Cohen Dean, M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Nir Yacov Barzilai M.D. | Founder and Member of Scientific Advisory Board |
| Dr. John M. Amatruda M.D., Ph.D. | Co-Founder |
| Jordyn Tarazi | Director of Investor Relations |